Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07819136) titled 'REC-7735 in Participants With Solid Tumors' on Sept. 8.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Recursion Pharmaceuticals Inc.

Condition: Solid Tumors

Intervention: Drug: REC-7735

Recruitment Status: Recruiting

Phase: Phase 1/Phase 2

Date of First Enrollment: September 2026

Target Sample Size: 90

Countries of Recruitment: United States

To know more, visit https://clinicaltrials.gov/study/NCT07819136

Published by HT Digital Content Services with permission from ...